Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
– Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in […]
– Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in […]
Initial Data from Ongoing MyPeak™-1 Phase 1b of TN-201 for MYBPC3-associated HCM Expected in Second Half of 2024 On Track […]
– Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an […]
Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today […]
Gemeinsame Bildungsinitiative konzentriert sich auf die Vorteile des Interferon-Gamma-Release-Assays (IGRA) für medizinisches Fachpersonal // Aktualisierte Richtlinien der US-amerikanischen CDC [...]
VANCOUVER, British Columbia, March 18, 2024 (GLOBE NEWSWIRE) — International Cobalt Corp. (“International Cobalt” or the “Company”) advises that it […]
BEDMINSTER, NJ, March 18, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – Peapack-Gladstone Financial Corporation (NASDAQ Global Select Market: PGC), the […]
PITTSBURGH, March 18, 2024 (GLOBE NEWSWIRE) — Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health […]
Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement […]
Surrey, BC, March 18, 2024 (GLOBE NEWSWIRE) — AAPKI Ventures Inc., formerly Pushfor Tech Inc. (“AAPKI” or the “Company”) (CSE: […]